Cytosorbents (CTSO) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Cytosorbents (NASDAQ: CTSO) recently:

• 11/11/2024 – Cytosorbents had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.
• 11/10/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/2/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/25/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/17/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/9/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/1/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/23/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/15/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Cytosorbents Price Performance

NASDAQ:CTSO traded up $0.07 during midday trading on Tuesday, hitting $1.00. 204,017 shares of the stock were exchanged, compared to its average volume of 124,726. The company has a market capitalization of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.56. The business has a 50-day moving average price of $1.13 and a two-hundred day moving average price of $1.01. The company has a current ratio of 2.12, a quick ratio of 1.71 and a debt-to-equity ratio of 0.82. Cytosorbents Co. has a one year low of $0.70 and a one year high of $2.15.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $9.89 million for the quarter, compared to analyst estimates of $9.73 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 108.52%. During the same period in the prior year, the firm posted ($0.14) earnings per share. Sell-side analysts predict that Cytosorbents Co. will post -0.31 EPS for the current year.

Hedge Funds Weigh In On Cytosorbents

Large investors have recently bought and sold shares of the stock. CM Management LLC boosted its stake in Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after buying an additional 25,000 shares during the last quarter. Sargent Investment Group LLC grew its position in shares of Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. acquired a new position in shares of Cytosorbents in the third quarter valued at approximately $51,000. Finally, Avenir Corp raised its position in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after buying an additional 121,294 shares during the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.